Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Raleigh Neurology Associates

Neither a doctor nor a teaching hospital

Research payments

$6,373,234

310 payments

Through program year 2025, Raleigh Neurology Associates is reported as receiving $6,373,234 in research payments, across 310 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $428,697 5
2024 Research $751,970 1
2023 Research $945,217 8
2022 Research $618,009 15
2021 Research $679,734 79
2020 Research $1,201,288 128
2019 Research $1,748,321 74

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $4,135,879 17 payments
  2. Biogen, Inc. $1,063,854 23 payments
  3. Eli Lilly and Company $407,403 13 payments
  4. Allergan Inc. $157,373 75 payments
  5. Jazz Pharmaceuticals Inc. $151,491 37 payments
  6. Genzyme Corporation $92,430 11 payments
  7. Teva Pharmaceuticals USA, Inc. $61,219 49 payments
  8. Genentech, Inc. $49,669 7 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $47,317 18 payments
  10. Amgen Inc. $37,350 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $2,694,735 9 payments
  2. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $867,992 3 payments
  3. A Pilot Open-Label, Randomized, Multi-Center, Parall El-Arm, of Acute VS Delay Ofatumumab Treatment D Uring An Acute Multiple Sclerosis Relapse $559,452 4 payments
  4. Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) $373,311 4 payments
  5. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $219,921 1 payment
  6. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $196,543 3 payments
  7. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $165,732 3 payments
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension $127,767 30 payments
  9. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia $122,114 1 payment
  10. Dimethyl Fumarate (DMF) Observational Study $119,856 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record